Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijid.2007.11.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Trials
October 2020
Community and Family Medicine, AIIMS Rishikesh, Rishikesh, India.
Objectives: 1. To compare the safety and efficacy of Hydroxychloroquine with Ribavirin and standard treatment in patients with non-severe COVID-19 infection 2. To compare the safety and efficacy of standard treatment, Lopinavir-ritonavir with Ribavarin, and Hydroxychloroquine with Ribavirin in patients with severe COVID-19 infection TRIAL DESIGN: The study is an Open label, Parallel arm design, stratified randomised controlled trial.
View Article and Find Full Text PDFImpact of health system protocol on patient qualification for influenza point-of-care testing.
J Am Pharm Assoc (2003)
August 2021
Background: Point-of-care testing (POCT) is a service that community pharmacies are implementing to increase patient access to care. Many pharmacies develop protocols with physicians to maximize patient qualification for POCT, while maintaining patient safety.
Objective: To determine the number of patients seen for influenza in the emergency department (ED) during the 2018-2019 season who would qualify for protocol-driven influenza testing.
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Lancet Respir Med
November 2019
Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Background: Since the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might have clinical benefit for patients with influenza infection, but definitive data do not exist. We aimed to evaluate the safety and efficacy of hIVIG in a randomised controlled trial.
Methods: This randomised, double-blind, placebo-controlled trial was planned for 45 hospitals in Argentina, Australia, Denmark, Greece, Mexico, Spain, Thailand, UK, and the USA over five influenza seasons from 2013-14 to 2017-18.
[Influenza A/H1N1v 2009 during pregnancy and breastfeeding: which antiviral to choose?].
Ann Pharm Fr
September 2010
Unité de Recherche en Pratique Pharmaceutique, Département de Pharmacie, Centre Hospitalier Universitaire Sainte-Justine, 3175 chemin de la Côte-Sainte-Catherine, Montréal H3T 1C5, Canada.
Pregnant women are at increased risk of severe complications associated with H1N1 pandemic influenza. Fever and inflammatory syndrome associated with the infection may also be deleterious for the developing fetus. Therefore, early antiviral treatment is recommended.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!